IMNM
insider transactionsImmunome Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 90d
-109.0K
25.4K buy · 134.4K sell
Net value · 90d
-$2.2M
$500.6K in · $2.7M out
Sentiment · 90d
Net selling
16% buying · 84% selling
Open-market trades · 90d
5
25.4K buy · 134.4K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Exercise·M
Max Rosett KEY
Chief Financial Officer · 10b5-1
$0
60.0K sh
Own New
-
Sell·S
Max Rosett KEY
Chief Financial Officer · 10b5-1
$1.1M
60.0K sh · $18.23
Own -53%
-
Exercise·M
Max Rosett KEY
Chief Financial Officer · 10b5-1
$63.0K
60.0K sh · $1.05
Own +111%
-
Grant·A
Director
$0
18.5K sh
Own New
-
Grant·A
Director
$0
9.9K sh
Own New
-
Grant·A
Director
$0
9.9K sh
Own New
-
Grant·A
Director
$0
9.9K sh
Own New
-
Grant·A
Director
$0
9.9K sh
Own New
-
Grant·A
Director
$0
9.9K sh
Own New
-
Exercise·M
Max Rosett KEY
Chief Financial Officer · 10b5-1
$0
39.7K sh
Own New
-
Exercise·M
Max Rosett KEY
Chief Financial Officer · 10b5-1
$0
31.8K sh
Own +113%
-
Sell·S
Max Rosett KEY
Chief Financial Officer · 10b5-1
$30.2K
1.3K sh · $22.48
Own -2%
-
Sell·S
Max Rosett KEY
Chief Financial Officer · 10b5-1
$1.4M
63.7K sh · $21.91
Own -53%
-
Exercise·M
Max Rosett KEY
Chief Financial Officer · 10b5-1
$53.6K
39.7K sh · $1.35
Own +50%
-
Exercise·M
Max Rosett KEY
Chief Financial Officer · 10b5-1
$33.4K
31.8K sh · $1.05
Own +67%
-
Sell·S
Chief Scientific Officer · 10b5-1
$204.2K
9.4K sh · $21.64
Own -30%
-
Other·G
Chief Scientific Officer
$0
6.3K sh
Own -17%
-
Buy·P
Clay B Siegall KEY
President and CEO
$500.6K
25.4K sh · $19.67
Own +4%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 15, 2026 | Max Rosett KEY 10b5-1 | Exercise M | 60.0K | $0 |
| Jun 15, 2026 | Max Rosett KEY 10b5-1 | Sell S | 60.0K | $1.1M |
| Jun 15, 2026 | Max Rosett KEY 10b5-1 | Exercise M | 60.0K | $63.0K |
| Jun 15, 2026 | James P Boylan | Grant A | 18.5K | $0 |
| Jun 10, 2026 | Sandra M Swain | Grant A | 9.9K | $0 |
| Jun 10, 2026 | Philip Wagenheim | Grant A | 9.9K | $0 |
| Jun 10, 2026 | Carol Schafer | Grant A | 9.9K | $0 |
| Jun 10, 2026 | James P Boylan | Grant A | 9.9K | $0 |
| Jun 10, 2026 | Isaac Barchas | Grant A | 9.9K | $0 |
| Apr 2, 2026 | Max Rosett KEY 10b5-1 | Exercise M | 39.7K | $0 |
| Apr 2, 2026 | Max Rosett KEY 10b5-1 | Exercise M | 31.8K | $0 |
| Apr 2, 2026 | Max Rosett KEY 10b5-1 | Sell S | 1.3K | $30.2K |
| Apr 2, 2026 | Max Rosett KEY 10b5-1 | Sell S | 63.7K | $1.4M |
| Apr 2, 2026 | Max Rosett KEY 10b5-1 | Exercise M | 39.7K | $53.6K |
| Apr 2, 2026 | Max Rosett KEY 10b5-1 | Exercise M | 31.8K | $33.4K |
| Apr 2, 2026 | Jack Higgins 10b5-1 | Sell S | 9.4K | $204.2K |
| Mar 30, 2026 | Jack Higgins | Other G | 6.3K | $0 |
| Mar 27, 2026 | Clay B Siegall KEY | Buy P | 25.4K | $500.6K |
About IMNM insider trading
This page tracks insider transactions for Immunome Inc. (IMNM) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.